893 high-priced prescription drugs subject to intensive review in second quarter

Published: 2006-06-05 06:56:00

Updated: 2006-06-05 06:56:00

A total of 893 high-priced ethical drugs with different brand-names will be subject to the government's intensive review from the second quarter of this year as part of its plan to induce the prescription of cost-effective drugs from hospitals and medical clinics, according to the Health Insuranc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK